Xarelto Lawsuits

You are here: Home » Xarelto Lawsuits

About Xarelto (rivaroxaban)

Xarelto (rivaroxaban) is a blood thinner (anticoagulant) medication approved by the U.S. Food and Drug Administration (FDA) in July 2011 to treat and reduce blood clots and strokes. Xarelto (rivaroxaban) is marketed as the new and easy alternative to warfarin (Coumadin), the go-to anticoagulant since the 1950’s. Unlike patients taking Xarelto (rivaroxaban) however, warfarin requires frequent blood monitoring, dosage adjustments, and dietary restrictions. Xarelto (rivaroxaban) requires only that the oral blood thinner be taken daily, with no dietary restrictions or routine monitoring. Xarelto (rivaroxaban) works by targeting certain proteins in the blood that form clots and interrupts the clotting process.

Who is prescribed Xarelto (rivaroxaban)?

Patients who are at risk of, or have atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE) and patients undergoing hip or knee replacement surgery are prescribed Xarelto (rivaroxaban). The dosage of Xarelto (rivaroxaban) differs among the type of treatment for which it is prescribed. Patients with atrial fibrillation are typically prescribed doses of 15mg and 20mg, and hip and knee replacement patients are prescribed a 10mg dose.

Problems with Xarelto (rivaroxaban)

Some patients who have taken Xarelto (rivaroxaban) have alleged that they experienced serious bleeding. Additionally, some patients, namely hip and knee replacement patients, have alleged that they experienced blood clots while taking Xarelto (rivaroxaban). Unlike patients bleeding on warfarin (Coumadin), which is easily reversed with a dose of Vitamin K, patients bleeding on Xarelto (rivaroxaban) is more problematic, because to-date, there is no antidote or reversal for the drug.

Free Legal Consultation

If you have been prescribed Xarelto and subsequently experienced internal bleeding please feel free to contact Charles E. Adler at 312-236-2700 or by e-mail at ca@adlerltd.com for a free legal consultation.